


Journal Pre-proof

Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India

Preethi Selvaraj, Sathish Muthu, Naveen Jeyaraman, Gollahalli Shivashankar
Prajwal, Madhan Jeyaraman



PII: S2213-3984(22)00023-9

DOI: <https://doi.org/10.1016/j.cegh.2022.100983>

Reference: CEGH 100983

To appear in: *Clinical Epidemiology and Global Health*

Received Date: 17 December 2021

Revised Date: 28 January 2022

Accepted Date: 3 February 2022

Please cite this article as: Selvaraj P, Muthu S, Jeyaraman N, Prajwal GS, Jeyaraman M, Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India, *Clinical Epidemiology and Global Health* (2022), doi: <https://doi.org/10.1016/j.cegh.2022.100983>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier B.V. on behalf of INDIACLEN.

**Incidence and Severity of SARS-CoV-2 Virus Post COVID-19 Vaccination: A Cross-
Sectional Study in India**

**Preethi Selvaraj^{1,2}, Sathish Muthu^{1,3}, Naveen Jeyaraman^{1,4}, Gollahalli Shivashankar
Prajwal^{1,5}, Madhan Jeyaraman^{1,6}**

¹ Research Associate, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India.

² Department of Community Medicine, SRM Medical College Hospital and Research Centre,
SRM Institute of Science and Technology, Chengalpattu, Tamil Nadu, India.

³ Department of Orthopaedics, Government Medical College and Hospital, Dindigul, Tamil
Nadu, India.

⁴ Fellow in Arthroplasty, Department of Orthopaedics, Atlas Hospitals, Tiruchirappalli, Tamil
Nadu, India.

⁵ Fellow in Spine Surgery, Department of Orthopaedics, Mallika Spine Centre, Guntur,
Andhra Pradesh, India.

⁶ Department of Orthopaedics, Faculty of Medicine - Sri Lalithambigai Medical College and
Hospital, Dr MGR Educational and Research Institute, Chennai, Tamil Nadu, India.

Address for the correspondence

Dr. Madhan Jeyaraman, Department of Orthopaedics, Faculty of Medicine - Sri Lalithambigai
Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, Tamil
Nadu, India. E-mail ID – madhanjeyaraman@gmail.com

1 **Incidence and Severity of SARS-CoV-2 Virus Post COVID-19 Vaccination:**

2 **A Cross-Sectional Study in India**

3 **Abstract**

4 **Introduction:** Several sociodemographic variables, including ethnic inequality, have been
5 identified as potentially influencing the uptake of COVID-19 vaccinations. To develop herd
6 immunity against COVID-19, at least 70-85% of the population must be vaccinated. As the
7 situation with COVID-19 changes, the public's perception keeps fluctuating. We designed a
8 survey to determine the prevalence of vaccinated individuals and the rate of infectivity post-
9 vaccination. We also aimed to study the clinical manifestations and infectivity of the SARS-
10 CoV-2 virus post-vaccination.

11 **Materials and methods:** A cross-sectional study was conducted from 10/05/2021 to
12 10/07/2021 across India through a pre-tested validated semi-structured self-administered
13 electronic questionnaire, to the study subjects with objectives explained and the confidentiality
14 of the data and results had been assured. The questionnaires were prepared using Google forms
15 and the link was sent across social media platforms such as WhatsApp, Facebook, and various
16 social platforms where people are actively engaged following the restrictions and protocols of
17 social distancing. General demographic data, followed by their lifestyle and comorbid
18 conditions, and data on their vaccination, infectivity, and side effects were collected.

19 **Results:** We included 2334 participants in the study, of which the majority of the study
20 participants were in the age group of 25-34 years (38.6%). 1729 were vaccinated individuals
21 of which 80.7% had received Covishield and 17.8% had received Covaxin. Around 61.1% have
22 received both doses among 1729 vaccinated individuals and 38.9% had received only one dose
23 of vaccine. The majority of the fully vaccinated individuals had a gap of 4-5 weeks for the
24 second dose (37.1%) followed by 5-6 weeks (11.2%). Post-vaccination 50.8% had experienced
25 muscle pain, 46% had experienced fatigue, 36.5% weakness, and 12.3% back pain. Among

26 vaccinated 26% turned out to be COVID-19 positive and 44.5% non-vaccinated got infected.
27 The odds of infection among non -vaccinated individuals was 2.27 times higher than vaccinated
28 individuals. Individuals who encountered the viral antigen for the second time experienced
29 either through vaccination or infection demonstrated exaggerated inflammatory response
30 which is explained by the antibody-dependent enhancement phenomenon without life-
31 threatening complications.

32 **Conclusion:** Although more than 50% of the vaccinated individuals experienced some form
33 of musculoskeletal side effects, we noted a high acceptance rate (74%) of vaccination among
34 the participants. The vaccinated individuals were two times safer from infection compared to
35 the non-vaccinated individuals.

36 **Keywords:** COVID-19; Vaccination; SARS-CoV-2 virus; Infectivity; Side-effects

37 **Introduction**

38 COVID-19 was declared a pandemic by the World Health Organization (WHO) in
39 March 2020.^{1,2} By 5th December 2021, 265 million cases had been documented globally, with
40 5.26 million deaths.³ COVID-19 preventive measures were practiced ineffectively in 2020,⁴
41 and India was hit by a second wave of the epidemic in mid-2021.⁵ In these conditions, mass
42 vaccination is the most effective way to combat the pandemic.⁶ Most coastal states have
43 achieved >50 percent adult vaccination since the introduction of COVID-19 vaccines, thanks
44 to pro-immunization initiatives. The average number of daily dosages delivered declined after
45 peaking at 6.44 million on June 26. Vaccine reluctance remained high in certain locations, with
46 more than 60% of the adult population remaining unvaccinated (as of June 2021). Several
47 sociodemographic variables, including ethnic inequality, have been identified as potentially
48 influencing the uptake of COVID-19 vaccinations.⁷

49 Vaccine apprehension may be trending, and the WHO has listed it as one of the biggest
50 dangers to world health.^{8,9} When compared to people of other races, African Americans had a

51 lesser acceptance of influenza and COVID-19 vaccinations. However, a larger perceived risk
52 of COVID-19 is a novel notion that has been shown to boost COVID-19 vaccination uptake
53 despite individual preferences.^{10,11,12}

54 To develop herd immunity against COVID-19, at least 70-85% of the population must
55 be vaccinated.¹³⁻¹⁵ As the situation with COVID-19 changes, the public's perception keeps
56 fluctuating. Pfizer revealed in November 2020 that its COVID-19 vaccine was 95% effective
57 in illness prevention, and the vaccine was thereafter released.¹⁶ Soon after, tales of negative
58 impacts inundated social media channels.¹⁷ As a result, individuals have become increasingly
59 skeptical of the COVID-19 vaccination.^{17,18}

60 We designed a survey study with the primary aim to determine the prevalence of
61 vaccinated individuals and the rate of infectivity post-vaccination. Secondary objectives were
62 to study the clinical manifestations and infectivity of the SARS-CoV-2 virus post-vaccination.

63 **Materials and methods**

64 A cross-sectional study was conducted from 10/05/2021 to 10/07/2021 across India
65 through a pre-tested validated semi-structured self-administered electronic questionnaire, to
66 estimate the prevalence of vaccinated individuals and the rate of infectivity post-vaccination.
67 The questionnaires were prepared using Google forms and the link was sent across social media
68 platforms such as WhatsApp, Facebook, and various social platforms where people are actively
69 engaged following the restrictions and protocols of social distancing.¹⁹ General demographic
70 data, followed by their lifestyle and comorbid conditions, and data on their vaccination,
71 infectivity, and side effects were collected. Informed consent was taken from the respondents
72 before the study and an option to terminate their participation was made available anytime they
73 desired in the form by default. The target sample size of participants was determined using the
74 epi info sample size calculator, the vaccine acceptance rate was estimated at 21%²⁰ and with a
75 3.3% confidence limit, 99.99 confidence level, the calculated sample size is 2334, adding 2%

76 non-response rate the final sample size is 2382. The Institutional Ethics Committee approval
77 was obtained for the conduction of the study.

78 Statistical software used to analyze data were MS Excel, SPSS for Windows Inc.
79 Version 25. Chicago, Illinois. Descriptive statistics were reported as mean and standard
80 deviation for continuous variables, frequencies (percentage) for categorical variables.
81 Proportions were compared using the chi-square test. Multiple logistic regression was used to
82 find the risk of disease positivity with demographic variables. For all comparisons, the p-value
83 of <0.05 was considered statistically significant.

84 **Results**

85 There were 2382 responses out of which 48 declined participation, hence the final
86 sample size was 2334. Table 1 gives the demographic characteristics of the study participants.
87 The majority of the study participants were in the age group of 25-34 years (38.6%) followed
88 by 18-24 years (36.8%), 10.3% in 35-44 years, 7.1% 45-54 years, 4.6% 55-64 years and 2.6%
89 65 years and above. There was a male preponderance with 52.9% were males. The majority of
90 them had Bachelor's degrees (51.4%) followed by master's degrees 25.5%. The majority of the
91 respondents were South Indians (39.8%) followed by North Indians (34.1%).

92 In our analysis, women (1243) felt the need to vaccinate more often than men (318)
93 ($p = 0.043$). They were more satisfied with the decision to vaccinate (women = 1251, men =
94 337; $p = 0.043$). People with higher education were more motivated to vaccinate themselves,
95 having known the rationale behind vaccination ($p = 0.002$) and they would choose a vaccine
96 based on the viral mRNA technology Pfizer (911) and Moderna (39).²¹

97 Lifestyle risk factors were tabulated in Table 2. There were about 17.8% smokers,
98 35.2% alcoholics, 37.7% of the participants who exercise daily, 16.8% having one or the other
99 co-morbidities, 10.9% had a history of surgical intervention for any bone, joint, muscle, soft

100 tissue, or nerve-related conditions. Overall, 74.1% were vaccinated with a minimum of one
101 dose of vaccine (Figure 1).

102 In our study among 1729 vaccinated individuals, 80.7% had received Covishield and
103 17.8% have received Covaxin. Around 61.1% have received both doses among 1729
104 vaccinated individuals and 38.9% had received only one dose of vaccine. The majority of the
105 fully vaccinated individuals had a gap of 4-5 weeks for the second dose (37.1%) followed by
106 5-6 weeks (11.2%) (Table 3). Post-vaccination 50.8% had experienced muscle pain, 46% had
107 experienced fatigue, 36.5% weakness, and 12.3% back pain. On the second dose, 55.9% didn't
108 experience any side effects followed by 15% muscle pain, 14% fatigue, 10.3% weakness, 3.4%
109 joint pain, and 3.1% back pain.

110 Among vaccinated 26% turned out to be COVID-19 positive whereas 44.5% among
111 non-vaccinated participants got infected. The odds of infection among non-vaccinated
112 individuals were 2.27 times higher than vaccinated individuals (Table 4).

113 Table 5 shows the association of clinical parameters and disease infectivity among
114 vaccinated individuals. The IL-6 count (pg/ml) during the active infective phase including
115 home-based care, ferritin level (ng/ml), and LDH level (U/L) were clinically raised among
116 vaccinated individuals compared to non-vaccinated individuals.

117 Discussion

118 The obtained research results indicate, the lack of reporting of side effects after the
119 administration of the COVID-19 vaccine by people. The COVID-19 vaccines can induce
120 moderate side effects after the first or second dose such as pain, redness, or swelling at the site
121 of vaccination along with fever, exhaustion, headache, nausea, vomiting, itching, chills, and
122 can infrequently cause anaphylactic shock.²² Quality documentation of the side effects of
123 vaccine is essential as it encourages healthcare providers to communicate in a systematic,
124 consistent, and effective manner.²³ In a study by Jęskowiak et al²⁴ statistically significant side

125 effects after receiving the vaccine were noted which include pain at the injection site (1275; $p <$
126 0.0001), redness at the injection site (696; $p < 0.0001$), and pain in the limb (766; $p < 0.0001$)
127 after the first dose of the vaccine, and after the second dose of the vaccine, a temperature above
128 38 °C (226; $p = 0.04$).

129 There was significant correlation between first dose of vaccine shot and side effects of
130 the vaccine along with occurrence of covid 19 infection. Among those non infected with covid
131 19, stronger side effects were reported after the second dose of the vaccine ($p < 0.001$). In our
132 study, post-second dose of vaccine, although around 55.9% didn't experience any side effects,
133 15% experienced muscle pain, 14% had fatigue, 10.3% with weakness, 3.4% had joint pain,
134 and 3.1% with back pain which is significantly high ($p < 0.001$) compared to the reported side
135 effects after the first dose of the vaccine in non-infected individuals.

136 In our study, association of clinical parameters and disease infectivity among
137 vaccinated individuals were assessed. The IL-6 count (pg/ml) during the active infective phase
138 including home-based care, ferritin level (ng/ml), and LDH level (U/L) were clinically raised
139 among vaccinated individuals significantly ($p < 0.001$) compared to non-vaccinated individuals.

140 In a study by Jęskowiak et al,²⁴ T-cell and antibody responses correlate with the severity
141 of COVID-19 clinical disease. Among those previously infected with covid 19, the adverse
142 effects reported after the first dose of vaccine may be because of antibody-dependent
143 enhancement (ADE). ADE refers to a situation in which antibodies that would normally lessen
144 the consequences of a viral infection end up doing the opposite: they fail to control the virus'
145 pathogenicity , or even enhance its virulence by facilitating its entry into the cell, or by
146 triggering an extensive reaction, causing damage to the host organs through hyper-
147 inflammation (cytokine storm).²⁵ In comparison to patients with severe disease, patients with
148 milder disease have more clonal expansion and less active proliferation in CD8 T-cells in the
149 bronchial fluid, as well as lower blood cytokine levels.²⁶

150 Our study has certain limitations. We could not achieve an overall representative data
151 across all the age groups subjected for vaccination. Secondly, the cross-sectional observational
152 nature of our study and the chosen sampling method may limit the validity of the results
153 obtained. On the other hand, the strengths of our work include the novelty of the topic, the large
154 sample size, and identification of the under-reported problem pertinent to the population
155 subjected to vaccination. It also clearly exposes the lack of awareness of the people to report
156 side effects for any health-related intervention being administered on large scale. In addition,
157 the study identified the most frequent side effects associated with vaccination, such as fatigue
158 and weakness.

159 **Conclusion**

160 Although more than 50% of the vaccinated individuals experienced some form of
161 musculoskeletal side effects such as muscle pain, and fatigue following first dose of
162 vaccination, we noted a high acceptance rate (74%) of vaccination among the participants. We
163 did not note such high prevalence of adverse events following second dose of vaccination. The
164 vaccinated individuals were 2.27 times safer from infection compared to the non-vaccinated
165 individuals.

166 **Acknowledgements:** Nil

167 **Conflicts of interests:** Nil

168 **Funding sources:** Nil

169 **References**

- 170 1. Weekly epidemiological update on COVID-19 - 30 March 2021. Accessed December 8,
171 2021. [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-2021)
172 [covid-19---31-march-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-2021)
- 173 2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Bio-Medica Atenei*
174 *Parm.* 2020;91(1):157-160. doi:10.23750/abm.v91i1.9397

- 175 3. WHO Coronavirus (COVID-19) Dashboard. Accessed December 8, 2021.
176 <https://covid19.who.int>
- 177 4. Girum T, Lentiro K, Geremew M, Migora B, Shewamare S. Global strategies and
178 effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and
179 isolation: a systematic review. *Trop Med Health*. 2020;48(1):91. doi:10.1186/s41182-020-
180 00285-w
- 181 5. Asrani P, Eapen MS, Hassan MI, Sohal SS. Implications of the second wave of COVID-
182 19 in India. *Lancet Respir Med*. 2021;9(9):e93-e94. doi:10.1016/S2213-2600(21)00312-X
- 183 6. Kumar S. Second wave of COVID-19: emergency situation in India. *J Travel Med*.
184 2021;28(7):taab082. doi:10.1093/jtm/taab082
- 185 7. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The current
186 second wave and COVID-19 vaccination status in India. *Brain Behav Immun*. 2021;96:1-
187 4. doi:10.1016/j.bbi.2021.05.018
- 188 8. Bendau A, Plag J, Petzold MB, Ströhle A. COVID-19 vaccine hesitancy and related fears
189 and anxiety. *Int Immunopharmacol*. 2021;97:107724. doi:10.1016/j.intimp.2021.107724
- 190 9. Nossier SA. Vaccine hesitancy: the greatest threat to COVID-19 vaccination programs. *J*
191 *Egypt Public Health Assoc*. 2021;96(1):18. doi:10.1186/s42506-021-00081-2
- 192 10. Karlsson LC, Soveri A, Lewandowsky S, et al. Fearing the disease or the vaccine: The case
193 of COVID-19. *Personal Individ Differ*. 2021;172:110590. doi:10.1016/j.paid.2020.110590
- 194 11. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of
195 COVID-19 risk perception with vaccine hesitancy over time for Italian residents. *Soc Sci*
196 *Med* 1982. 2021;272:113688. doi:10.1016/j.socscimed.2021.113688

- 197 12. Motta M, Sylvester S, Callaghan T, Lunz-Trujillo K. Encouraging COVID-19 Vaccine
198 Uptake Through Effective Health Communication. *Front Polit Sci.* 2021;3:1.
199 doi:10.3389/fpos.2021.630133
- 200 13. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity
201 to SARS-CoV-2 infection by mass vaccination. *Lancet Lond Engl.* 2020;396(10263):1614-
202 1616. doi:10.1016/S0140-6736(20)32318-7
- 203 14. Kaplan RM, Milstein A. Influence of a COVID-19 vaccine's effectiveness and safety
204 profile on vaccination acceptance. *Proc Natl Acad Sci.* 2021;118(10).
205 doi:10.1073/pnas.2021726118
- 206 15. Anand P, Stahel VP. Review the safety of Covid-19 mRNA vaccines: a review. *Patient Saf*
207 *Surg.* 2021;15(1):20. doi:10.1186/s13037-021-00291-9
- 208 16. Jr BL. Pfizer says final data analysis shows Covid vaccine is 95% effective, plans to submit
209 to FDA in days. CNBC. Published November 18, 2020. Accessed December 8, 2021.
210 [https://www.cnbc.com/2020/11/18/coronavirus-pfizer-vaccine-is-95percent-effective-](https://www.cnbc.com/2020/11/18/coronavirus-pfizer-vaccine-is-95percent-effective-plans-to-submit-to-fda-in-days.html)
211 [plans-to-submit-to-fda-in-days.html](https://www.cnbc.com/2020/11/18/coronavirus-pfizer-vaccine-is-95percent-effective-plans-to-submit-to-fda-in-days.html)
- 212 17. Alfatease A, Alqahtani AM, Orayj K, Alshahrani SM. The Impact of Social Media on the
213 Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study from Saudi Arabia.
214 Patient preference and adherence. 2021;15:2673.
- 215 18. Rosenberg H, Syed S, Rezaie S. The Twitter pandemic: The critical role of Twitter in the
216 dissemination of medical information and misinformation during the COVID-19
217 pandemic. *Cjem.*:1-4. doi:10.1017/cem.2020.361

- 218 19. Nilima N, Kaushik S, Tiwary B, Pandey PK. Psycho-social factors associated with the
219 nationwide lockdown in India during COVID-19 pandemic. *Clinical Epidemiology and*
220 *Global Health*. 2021 Jan 1;9:47-52.
- 221 20. Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19
222 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review. *Front Public Health*.
223 2021;9:1152. doi:10.3389/fpubh.2021.698111
- 224 21. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison
225 of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and
226 Moderna Vaccines. *Eur Rev Med Pharmacol Sci*. 2021;25(3):1663-1669.
227 doi:10.26355/eurrev_202102_24877
- 228 22. Khan MA, Nilima N, Prathibha J, Tiwary B, Singh M. Documentation compliance of in-
229 patient files: a cross sectional study from an east India state. *Clinical Epidemiology and*
230 *Global Health*. 2020 Dec 1;8(4):994-7.
- 231 23. Jeon M, Kim J, Oh CE, Lee JY. Adverse Events Following Immunization Associated with
232 Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events
233 Reporting System. *J Korean Med Sci*. 2021;36(17):e114. doi:10.3346/jkms.2021.36.e114
- 234 24. Jęskowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The Incidence and Severity of
235 Post-Vaccination Reactions after Vaccination against COVID-19. *Vaccines*.
236 2021;9(5):502. doi:10.3390/vaccines9050502
- 237 25. Danchin A, Turinici G. Immunity after COVID-19: Protection or sensitization? *Math*
238 *Biosci*. 2021;331:108499. doi:10.1016/j.mbs.2020.108499

- 239 26. Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell
240 response in protective immunity against SARS-CoV-2? *Vaccine X*. 2020;6:100076.
241 doi:10.1016/j.jvacx.2020.100076

Journal Pre-proof

Table 1: Demographic characteristics of the study participants (N=2334)

Variable	Frequency	Percentage
Age		
18-24	860	36.8
25-34	901	38.6
35-44	240	10.3
45-54	166	7.1
55-64	108	4.6
65 and above	59	2.6
Gender		
Male	1234	52.9
Female	1100	47.1
Education		
Bachelor's degree	1199	51.4
Doctorate	222	9.5
High school graduate	270	11.6
Master's degree	595	25.5
None of the above	48	2.0
Region		
Central India	200	8.6
East India	138	5.9
North India	796	34.1
North-Eastern India	67	2.9
North-Western India	29	1.2
South India	929	39.8
Western India	175	7.5

Table 2: Distribution of lifestyle risk factors among the study participants (N=2334)

Variable	Frequency	Percentage
History of smoking		
Yes, Regular active smoker	99	4.2
Yes, occasional active smoker	215	9.2
Yes, passive smoker	102	4.4
No history of smoking	1918	82.2
History of alcohol consumption		
Yes, consume regularly	42	1.8
Yes, consume occasionally	779	33.4
No history of alcohol consumption	1513	64.8
Exercise daily		
Yes	881	37.7
No	1453	62.3
Co-morbidity		
Yes	391	16.8
No	1943	83.2
Listed co-morbidities		
Asthma	57	2.4

CVD	15	0.6
CKD	11	0.5
COPD	13	0.6
DM	45	1.9
DM & HTN	32	1.4
HTN	111	4.8
Thyroid	107	4.6
Any history of surgical intervention for any bone, joint, muscle, soft tissue or nerve related conditions		
Yes		
No	255 2079	10.9 89.1
How recently were u been operated		
< 1 month ago		
>1 year ago	17	0.7
1-6 months ago	274	11.7
6-12 months ago	17 11	0.7 0.5
Vaccinated		
Yes	1729	74.1
No	605	25.9

Table 3: Distribution of parameters on vaccine among the study participants (n=1729)

Variable	Frequency	Percentage
Type of vaccine		
AstraZeneca	1	0.06
Coronavac	3	0.2
Covaxin	308	17.8
Covishield	1395	80.7
Moderna	5	0.3
Pfizer 13	13	0.75
Sputnik V	4	0.23
Are you full vaccinated (both dosages of covishield, covaxin, sputnik V)		
Yes	1056	61.1
No	673	38.9
What was the period of difference for taking the second dosage of the COVID-19 vaccine?		
4-5 weeks	642	37.1
5-6 weeks	196	11.3
6-7 weeks	140	8.1
7-8 weeks	130	7.5
8-12 weeks	166	9.6
More than 12 weeks	91	5.3

Did you experience any musculoskeletal pain after the first dose of the COVID-19 vaccination?		
Backpain	213	12.3
Weakness	631	36.5
Fatigue	796	46.0
Joint pain	232	13.4
Muscle pain	878	50.8
None	421	24.3
Did you experience any musculoskeletal pain after the second dose of the COVID-19 vaccination?		
Backpain	53	3.1
Weakness	178	10.3
Fatigue	243	14.1
Joint pain	59	3.4
Muscle pain	260	15.0
None	968	55.9

Table 4: Association of vaccine and severity of the disease (N=2334)

Variable	Vaccinated (n=1729)	Non-vaccinated (n=605)	Chi-square (df) p	OR (95% CI)
COVID-19 positive				
Yes	450 (26%)	269 (44.5%)	71.45	1
No	1279 (74%)	336 (55.5%)	(1) <0.001	2.27 (1.87 to 2.76)
Severity of infection				
Mild	309 (17.9%)	166 (27.4%)		2.045 (1.635-2.557)
Moderate	126 (7.3%)	83 (13.7%)	80.640	2.507 (1.854-3.392)
Severe	15 (0.9%)	20 (3.3%)	(3)	5.075 (2.571-10.020)
No infection	1279 (74%)	336 (55.5%)	<0.001	1

Table 5: Association of clinical parameters and disease infectivity among vaccinated individuals (n=719)

Variable	Vaccinated (n=450)	Non-vaccinated (n=269)	Chi-square (df) p
What was your treatment plan?			
Both home-based + ICU	35 (7.8)	24 (8.9)	
Home isolation	352 (78.2)	204(75.8)	0.81
Hospital-based care with ICU	26 (5.8)	15 (5.6)	(3)
Hospital-based care with oxygen support	37 (8.2)	26 (9.7)	0.84
If hospital-based care what was the duration for the same?			
>6 weeks	37 (8.2)	23 (8.6)	
1-2 weeks	47 (10.4)	26 (9.7)	3.69
2-4 weeks	11 (2.4)	14 (5.2)	(3)
4-6 weeks	5 (1.1)	2 (0.7)	0.29
Maximum CRP count (mg/dl) during the active infective phase including home-based care			
0-6 (normal)	101 (22.4)	60 (22.3)	
<26 (mild)	106 (23.6)	56 (20.8)	2.378
26-100 (moderate)	56 (12.4)	33(12.3)	(4)
>100 (severe)	13 (2.9)	13 (4.8)	0.67
Not aware	174 (38.7)	107 (39.8)	
What was the maximum reported range of IL-6 count (pg/ml) during the active infective phase including home-based care			
0-7 (normal)	106 (23.6)	48 (17.8)	
<15 (mild)	52 (11.6)	21 (7.8)	8.88 (5)
15-100 (moderate)	42 (9.3)	27 (10)	0.07
100-500 (severe)	6 (1.3)	3 (1.1)	
>500 (critical)	0	1 (0.4)	
Not aware	244 (54.2)	169 (62.8)	
Maximum reported range of D-dimer level (mcg/ml) during the active infective phase			

including home-based care			
<0.5 (normal)	144 (32)	78 (29)	4.478 (3)
<1 (mild)	61 (13.6)	32 (11.9)	0.21
>1 (moderate-severe)	43 (9.6)	18 (6.7)	
Not aware	202 (44.9)	141 (52.4)	
Maximum reported range of ferritin level (ng/ml) during the active infective phase including home-based care			
<13	55 (12.2)	30 (11.2)	9.768 (3)
13-150	56 (12.4)	24 (8.9)	0.02
>150	73 (16.2)	27 (10)	
Not aware	266 (59.1)	188 (69.9)	
Maximum reported range of your LDH level (U/L) during the active infective phase including home-based care			
0-250	61 (13.6)	25 (9.3)	12.434 (2)
>250	95 (21.1)	35 (13)	0.002
Not aware	294 (65.3)	209 (77.7)	
Maximum reported range of your ESR count (mm/hr) during the active infective phase including home-based care			
0-22	95 (21.1)	48 (17.8)	1.934 (2)
>22	70 (15.6)	37 (13.8)	0.38
Not aware	285 (63.3)	184 (68.4)	




Figure 1: Distribution of percentage of vaccinated individuals among the study participants (N=2334)




Figure 2: Distribution of infectivity and severity among vaccinated individuals (n=1729)